News for Chimerix, Inc. (CMRX)

We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where Chimerix Inc.

Net Loss: Reported a net loss of $23.0 million for Q4 2024, translating to $0.25 per share, slightly better than the estimated EPS of -$0.26.Revenue: Achieved

New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Ac

PR NewswireNEW YORK, March 17, 2025 NEW YORK, March 17, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following

NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations

PR NewswireNEW YORK, March 11, 2025 NEW YORK, March 11, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following

We recently compiled a list of the 10 Micro-, Small-Cap Firms Were Last Week's Top Performers. In this article, we are going to take a look at where Chimerix, Inc.

NEW YORK, March 08, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations

DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Dir

**media[560522]**

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. ( CMRX) to Jaz

Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.

North Carolina-based Chimerix, Inc. (CMRX) is up over 69 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per sha

Transaction Overview On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a strategic move by acquiring an additional 9,536,647 shares in Biof

**media[527622]**

**media[523712]**

One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the recent past losers.

Chimerix’s dordaviprone shows potential for glioma treatment with a possible FDA approval by 2025. Read why CMRX stock is a strong growth candidate.